Purpose: Head and neck squamous cell carcinomas (HNSCC) are characterized by high morbidity and mortality, largely due to the high invasive and metastatic potential of these tumors, high recurrence rates, and low treatment responses. Proteinases have been implicated in several aspects of tumor growth and metastasis in a broad range of tumors including HNSCC.
Head and neck squamous cell carcinoma (HNSCC) can be defined as a malignant tumor derived from the squamous epithelial cells that line the upper aerodigestive tract, which extends from the surface of the lips to the cervical surface of the esophagus. HNSCC is the fifth most common cancer worldwide and, in 2002, was the cause of over 300,000 deaths worldwide (1) . The overall survival rates of HNSCC patients (∼50%) have remained unaltered for over 20 years. The presence of lymph node metastases is the single most important predictive factor for HNSCC patients resulting in a 50% decrease in survival (2, 3) .
The degradome comprises both the complete set of proteases (also known as peptidases and proteinases) expressed by a cell, tissue, or organism at a given time, and the substrate repertoire of a given proteinase (4) . There is a well-established association between matrix proteolysis and cancer invasion and metastasis, and the proteinases of every class have been linked to malignancy and invasion of tumor cells (5) . However, through the study of transgenic models and the identification of further proteinases and proteinase substrates, it is now clear that the proteinases also play crucial roles in early tumorigenic events such as angiogenesis, apoptosis, cell dissociation, and cell migration (6) . In addition to their recognized roles in extracellular matrix degradation, secreted proteinases also play important roles in controlling the bioactivity of cytokines and growth factors and in the shedding of cell surface growth factors and adhesion receptors (7, 8) . Thus, proteinases have complex influences on the tumor microenvironment and there is growing evidence that many proteinases can act in an antitumorigenic fashion in addition to their classic proinvasive and prometastastic roles (9) .
Matrix metalloproteinases (MMPs) are a zinc-dependent metalloproteinase subfamily consisting of 23 members that can collectively degrade all major components of the extracellular matrix (10) . Most MMPs are secreted; however, the membrane-type MMPs contain either a transmembrane domain or glycosylphosphatidylinositol anchor locating them to the cell surface. The main inhibitors of MMP activity are tissue inhibitors of the metalloproteinases (TIMPs), a group of four secreted proteins that reversibly bind and inactivate MMPs in a 1:1 stoichiometric manner (11) . TIMPs differ in their expression patterns and inhibitory activities toward certain MMPs (11) . Moreover, TIMP2 can also be secreted in a complex with proMMP2 and function in MMP2 activation (12) .
The A disintegrin and metalloproteinases (ADAMs) are a group of 21 human transmembrane metalloproteinases that belong to the same family of zinc proteinases as the MMPs and which contain a unique integrin receptorbinding disintegrin domain (8) . All ADAMs are not catalytically active, as only approximately half contain the conserved catalytic-site consensus motif (HEXXH) in their metalloproteinase domain (7) . The ADAMs with thrombospondin motifs (ADAMTSs) is a group of 19 secreted metalloproteinases, which are close relatives of the ADAMs. Instead of the transmembrane domains and cytoplasmic tails of the ADAMs, the ADAMTSs contain a variable number of thrombospondin-like motifs (13, 14) . The TIMPs also inhibit the activity of selected ADAM and ADAMTS members (15) (16) (17) .
Thus far, several studies have explored proteinase involvement in HNSCC, mainly using immunohistochemical methods to measure the presence of MMPs in tissue sections. Indeed, most proteinases studied and implicated in HNSCC are increased in expression in tumor tissues and metastases, and are therefore linked to HNSCC progression at some level in at least one study. However, the observations are often contradictory and thus the exact role of these factors in HNSCC pathology remains unclear. There are many reasons for this; for instance, diverse techniques, the lack of reliable antibodies for many proteinases, the low patient numbers, and the pooling of tumors from different sites. It is consensus that MMP2, 7, 9, 10, 13, and TIMP1 are particularly involved in HNSCC pathogenesis and progression (18) (19) (20) . There are further suggestions of the involvement of MMP1, 3, 11, 14, and TIMP2, but no other MMPs or TIMPs have been studied (18) (19) (20) . In contrast, the ADAM and ADAMTS families have not been extensively studied in this tumor type. There is evidence for their involvement in HNSCC as both ADAM10 (21) and ADAM12 (22) are overexpressed in oral HNSCCs.
In this study, we have investigated the expression of the entire MMP and TIMP families, and subsets of the ADAMs and ADAMTSs in a large cohort of tumor samples of HNSCC patients and cell lines established from these tumors. These data provide a descriptive degradome of HNSCC tissues and identify several novel proteinases, which can serve as molecular markers for the classification and prognosis of this malignant tumor.
Materials and Methods
Tissue samples and cDNA preparation. This study received approval from the Norwich Local Research Ethics Committee, the Norwich and Waveney Research Governance Committee, and the Partners in Cancer Research Tissue Bank Committee. Studies at the University of Turku were approved by the Joint Ethical Committee of the University of Turku and Turku University Hospital. Participants gave their informed consent and the study was conducted according to the declaration of Helsinki.
Forty-one HNSCC tissue samples sets (each containing of adjacent, margin, and center tumor tissues) were obtained from the Norfolk and Norwich University Hospital Tissue Bank. Detailed procedures for obtaining informed patient consent, sample collection, processing and storage, and finally, collection of relevant clinical information has already been described (23) . Forty-two HNSCC center tumor samples were obtained from surgically removed tumors in Turku University Hospital between years 2003 and 2005 from both genders (ranging in age from 39-86 y). The clinical parameters corresponding to the tumors are shown in Table 1 . As a control, 13 normal nonneoplastic tissue samples of uvular, tonsil, and soft palate mucosa of patients were obtained during tonsillectomy or surgery for sleep apnea in Turku University Hospital. Total RNA was isolated
Translational Relevance
This study provides novel information on the proteinases and their inhibitors participating in the progression of head and neck squamous cell carcinomas (HNSCC). The study cohort is exceptionally large, enabling us to evaluate the results in the light of previous findings in the field. In addition, several HNSCC-associated degradome components presented for the first time in this study serve as a valuable source of novel diagnostic, predictive, and prognostic factors, as well as follow-up markers for the early detection of metastases and efficacy of therapy. Furthermore, these degradome components provide potential targets for novel treatment modalities in HNSCC patients. from the tissue samples by homogenizing in RNA bee (Biogenesis Ltd) using the Qiagen TissueLyser (Qiagen) and then the SV Total RNA isolation kit or RNA Easy Mini kit (Promega) as previously described (24, 25) or using the acid-guanidium thiocyanate-phenol-chloroform method (26) . RNA quality and concentration was then determined using the NanoDrop ND-1000 UV-Vis Spectrophotometer (Labtech). Total RNA (1 μg) was reverse transcribed with 2 μg random hexamers (Amersham Pharmacia Biotech) and 200 units of SuperScript II reverse transcriptase (Invitrogen) according to the manufacturer's instructions using a GRI DNA Engine (GRI). The cDNA was diluted 1:100 with PCR grade water and stored at −20°C.
Cell cultures. Human HNSCC cell lines (n = 34) were established at the time of operation from HNSCCs (27) . The clinical data of the corresponding tumors are shown in Table 1 . Cells were cultured in DMEM supplemented with 6 nmol/L glutamine, nonessential amino acids, and 10% FCS. Normal human epidermal keratinocytes (NHEK-PC) were purchased from PromoCell and other primary NHEKs (n = 8) were established from skin samples, and cultured in Keratinocyte Basal Medium 2, supplemented with SingleQuots (Cambrex Bioscience), as previously described (28) . Total RNA was extracted from cultured cells using the Trizol reagent (Invitrogen) and cDNA was synthesized as above.
Quantitative real-time PCR. For qPCRs, specific primers and probes for all human MMPs, TIMPs, catalytically active ADAMs, and some ADAMTSs were designed as previously described (Table 2; refs. 24, 25, 29) . The 18S rRNA was used as an endogenous control to normalize for differences in the amount of total RNA in each sample, using previously validated procedures (30) . PCRs were done as previously described (29) using the ABI 7700 real-time PCR machine (Applied Biosystems) with each reaction containing 5 ng of reverse-transcribed RNA (1 ng for 18S) in a 25-μL reaction. The relative RNA levels in each sample were determined by performing standard curves for all target genes covering 1 to 0.0625 ng of RNA for 18S and 20 to 0.5 ng RNA for all other genes.
Protein extraction and quantification. Frozen tissue samples were homogenized in ice-cold protein extraction buffer (pH 6.7) containing 500 mmol/L Tris (Melford Laboratories Ltd), 200 mmol/L M NaCl (Sigma-Aldrich), 10 mmol/L CaCl 2 (Sigma-Aldrich), 1% (v/v) Triton X-100 (BDH), and 1 complete, Mini, EDTA-free proteinase inhibitor cocktail tablet (Roche Diagnostics Ltd) per 10 mL. Samples were then placed on ice for 1 h, before centrifugation at 6,000 rpm for 1 min. The resultant protein containing supernatant was then stored at −20°C. The protein content for each sample was quantified using the BCA protein assay kit (Perbio Scientific UK Ltd). However, due to the high Triton X-100 content of the protein extraction buffer, the samples required dilution in PBS at least 1:10.
Zymography. 
(Continued on the following page) used to track protein migration. The proteins were transferred to Immobilon-P SQ membrane (Millipore) at 45 V overnight in TG transfer buffer (Bio-Rad Laboratories Ltd) containing 20% (v/v) methanol (Fisher-Scientific). The membrane was then washed in wash buffer containing 20 mmol/L Tris-HCl (pH 7.6), 1.3 mol/L NaCl, and 0.1% (v/v) Tween 20 (Sigma-Aldrich) before blocking for 1 h in wash buffer containing 5% Marvel (Premier International Foods Ltd). After further washes in wash buffer, the membrane was incubated with the primary antibody [sheep anti-human MMP3 at 20 μg/mL, MMP14 at 5 μg/mL (31) according to the manufacturers instructions] in blocking buffer overnight at 4°C. The membrane was then washed before applying the secondary antibody [peroxidase anti-sheep (Stratech Scientific Ltd) or peroxidase anti-rabbit (Vector Laboratories)] according to manufacturers instructions, for 1 h at room temperature. Finally the membrane was washed and visualized using the ECL Plus detection kit (GE Healthcare UK Ltd). After use, the membranes were stained for total protein in Coomassie stain for 30 min and then destained in 10% (v/v) acetic acid and 30% (v/v) isopropanol.
Expression of ADAM8, ADAM9, and ADAM28 in NHEKs and HNSCC cells was analyzed by Western blotting. Cell lysates from HNSCC and normal keratinocyte cultures were collected and aliquots were fractionated on SDS-polyacrylamide gels, transferred to Hybond enhanced chemiluminescence nitrocellulose membrane (Amersham Pharmacia Biotech. The membranes were blocked using 5% skimmed milk. Proteins were detected using goat anti-human ADAM8 antibodies (AF1031) or goat antihuman ADAM9 polyclonal antibodies (AF939; both from R&D Systems), mouse monoclonal ADAM28 antibody (297-2F3; ref. 32) , and peroxidase-conjugated secondary antibodies. The blots were visualized by enhanced chemiluminescence detection system (Amersham Pharmacia Biotech).
Statistical analyses. Statistical analysis to compare expression between the tissue types and the clinicopathologic variables was done using the Kruskall-Wallis ANOVA
MMP-23
Forward primer
Forward primer 5′-GGGCCCACGATTTGCA -3′ Reverse primer 5′-TGAACCTTCCTGTCTTTCAATTTTACT -3′ Probe 5′-FAM-AGAACATTGCCCTACCTGCCACCAAAC-TAMRA -3′ 
Results
Global analysis of the expression of degradome components in distinct compartments of HNSCC tumor tissue. To obtain a comprehensive view of the expression of degradome components in distinct compartments of HNSCCs, quan- Table 3 .
of approximate overall levels of expression between different genes (29) . In addition, scatter plots for selected genes are shown in Fig. 1B , allowing the precise quantification of changes in expression for single genes between different specimens and comprehensive comparison between distinct tumor compartments is shown in Table 3 . The data show that (Fig. 1A) . The majority of the MMPs were expressed in tumor tissues, both in the center and the invasive margin of the tumor and the expression was in general increased compared with normal tissue (Table 3 ; Fig. 1A ). Expression of most MMPs was also noted in the adjacent tissue, and for some MMPs, the level was lower than in tumor tissue. The only MMP with significantly decreased expression in the center tissues compared with adjacent tissues was MMP27 (Table 3) . Abundant expression of members of the ADAM family was noted in the tumor tissue and adjacent tissue, and the expression levels were also largely increased in tumor tissues, with no ADAM showing significantly decreased expression (Fig. 1A) . Members of the ADAMTS family examined showed low expression in normal tissue with no detectable expression of ADAMTS8. High or moderate expression of all ADAMTSs was noted in the tumor tissue (Fig. 1A) . ADAM8 and ADAM28 were expressed in all compartments of the tumor and there was no marked difference between expression in tumor tissue and adjacent tissue (Table 3 ; Fig. 1B ). In comparison, ADAMTS8 expression was higher in the tumor center with low expression in the tumor margin, which was opposite to the pattern for ADAMTS5, 9, and 15, which were expressed at a lower level in the center tumor samples (Table 3 ; Fig. 1A ). Of the proteinase inhibitors, markedly increased expression of TIMP2 was noted in tumor tissues, whereas the expression in normal tissue samples was undetectable (Fig. 1A and B) . TIMP4 expression was very low in normal oral tissue, highest in tissue adjacent to tumor, and decreasing in the tumor margins and center (Table 3 ; Fig. 1A and B) . No expression of MMP20, 21, and 26 was found in any of these tissues, with median CT values of 40 (Fig. 1A) .
Proteinase protein levels in HNSCC tissues. Western blot analysis and gelatin zymography were done to assess the levels of selected proteinases, i.e., MMP2, MMP3, MMP9, and MMP14 in the adjacent, margin, and center tissues. The protein levels of these proteinases largely followed the mRNA levels increasing in the tumor margin and center compared with the adjacent tissues (Fig. 2) . Coomassie blue total protein staining confirmed even protein loading for tissue samples used in Western blotting. Consistent with the mRNA and protein increases seen for MMP14, the major enzyme responsible for the activation of pro-MMP2 in the tumor margin and center samples, increased levels of active MMP2 were noted in these samples by zymography.
Degradome component expression by HNSCC tumor cell lines. To verify the specific expression of MMPs, ADAMs, and ADAMTSs by tumor cells of HNSCCs, we performed expression profiling of a large panel of cell lines (n = 34) established from these tumors. Based on the analysis of the in vivo tissue samples, the quantitative real-time RT-PCR expression data for selected MMPs, TIMPs, ADAMs, and ADAMTSs profiled are summarized in Fig. 3A . The data show that most of the MMPs are expressed at high level in Fig. 2 . Expression MMP 3, 14, 2, and 9 in distinct compartments of head and neck SCC tumors. Protein was extracted from matched normal (N), margin (M), and center (C) tissues of six HNSCC patients (1-6). Western blotting was done on four of these protein sets for MMP3 and MMP14 (A, top. Arrows, proMMP3 (57 kDa; left top) and proMMP14 (66 kDa) and active MMP14 (54 kDa; right top). After Western blotting, the membrane was stained for total protein using Coomassie blue stain (B, bottom). Gelatin zymography was done using protein extracted from matched normal, margin, and center tissues of six HNSCC patients (1-6). A positive control was loaded onto the zymography identifying an ∼95-kDa band of latent MMP-9 and an ∼72-kDa band of latent MMP-2.
HNSCC tumor cell lines compared with normal keratinocytes with only few exceptions. The highest increases in the levels in SCC cells were noted in MMP2, MMP7, MMP10, MMP11, MMP13, MMP14, MMP16, MMP17, MMP23, MMP24, and MMP25 (Fig. 3A) . The only MMP showing decreased expression in SCC cells was MMP27 Fig. 3 . Expression of degradome components by head and neck SCC tumor cell lines. A, expression of degradome components in HNSCC cell lines (n = 34) was determined by quantitative real-time RT-PCR, normalized to 18S rRNA levels in each sample, and compared with the levels in NHEKs (1.00). Statistical comparison between HNSCC cell lines and NHEKs was performed using Wilcoxon rank-sum test and P values for 0.01 to 0.05 (*), 0.001 to 0.01 (**), and <0.001 (***) are shown. B, expression of ADAM8, ADAM9, and ADAM28 by NHEKs and selected HNSCC cell lines (n = 9) were determined by Western blotting of cell lysates. Left, positions of molecular weight markers (in kDa).
(P < 0.05). Among the ADAMs analyzed, ADAM17 and ADAM28 were expressed at higher levels in SCC cells. ADAMTS8 was the only analyzed degradome component found absent in all normal epidermal keratinocyte samples, with median CT values of 40. ADAMTS1 and ADAMTS15 were clearly upregulated in SCC cells compared with normal keratinocytes. In contrast, the expression of ADAMTS5 and ADAMTS9 was clearly decreased in SCC cells. Expression of TIMPs was observed both in SCC cells and normal keratinocytes with TIMP4, and especially TIMP2, showing significantly increased expression in tumor cells. In summary, the alterations in proteinase were analyzed between these groups using Mann-Whitney nonparametric unpaired t testing. Selected proteinases that displayed significant changes between these groups are shown.
The median values are shown as horizontal bars within the data and significant differences are represented as *, **, or *** for P values of 0.01 to 0.05, 0.001 to 0.01, or <0.001, respectively. Where there are more than two groups for statistical testing, horizontal bars identify the two parameters between which significant differences were found.
expression levels in HNSCC cell lines were in good agreement with the results obtained with tumor material (Figs.  1A and B, and 3A) .
Expression of ADAMs by HNSCC tumor cells. The expression of novel HNSCC proteinases, ADAM8, ADAM9, and ADAM28, was further analyzed by Western blotting of lysates of cultured HNSCC cells. A 100-kDa band was noted in the ADAM8 Western blot in HNSCC tumor cells (Fig. 3B) . ADAM8 is produced as a 92-kDa proform, but due to posttranslational modifications, its molecular mass on the cell surface is ∼100 kDa (33) , corresponding in size to the largest band seen in the HNSCC samples (Fig. 3B) . A 72-kDa band was also observed, apparently representing a form of ADAM8 generated by proteolytic removal of the prodomain. The smallest species, ∼50 kDa in size, may represent ADAM8 lacking the metalloproteinase domain. A marked variation in the expression levels of ADAM8 protein between distinct HNSCC cell lines analyzed was noted (Fig. 3B) , and the levels in individual cell lines correlated well with the corresponding mRNA levels (data not shown). Production of an ∼84-kDa mature ADAM9 was detected in all HNSCC cell lines examined, and the expression levels were also variable between individual cell lines (Fig. 3B) and correlated with the corresponding mRNA levels (data not shown). The 60-to 65-kDa band detected may represent an ADAM9-like protein, which is also detected with the ADAM9 antibody used (34) . In the same HNSCC cells, ADAM28 bands of 55 and 42 kDa in size were detected in most HNSCC cell lines (Fig. 3B) . The 55-kDa band is considered to be propeptide-deleted membrane-bound ADAM28 and the 42-kDa form of ADAM28 is an active form (32) . In summary, these results show that ADAM8, ADAM9, and ADAM28 are readily expressed by tumor cells of HNSCCs.
Degradome component expression and HNSCC clinicopathologic parameters. Clinical information about primary tumor location, size, histopathologic grade, and presence of lymph node metastases was available for all 83 HNSCC patients. The quantitative real-time RT-PCR expression data were further analyzed for differences in degradome gene expression with respect to these clinical parameters. In general, there were few significant differences in degradome gene expression between primary tumors differing in location, grade, and size. However, certain differences were noted in tumors based on anatomic location. MMP8 and 10 were mainly expressed by tumors of oral cavity and larynx and MMP17 in tumors of oral cavity (Fig. 4A and not  shown) . Increased expression of MMP1 and 3 was seen in tumors of the oral cavity compared with the pharynx (data not shown). In contrast, ADAM8, 9, and 28 were expressed preferably in SCCs of pharynx (data not shown).
Certain significant differences in expression were also noted between tumors representing different histopathologic grades, i.e., different levels of differentiation. Specifically, there was a significant decrease in the expression of MMP2 with tumor grade, the highest expression being noted in well differentiated (grade 1) tumors (Fig. 4B) .
Similarly, a decrease in MMP10 expression was noted in poorly (grade 3) differentiated tumors. Interestingly, the expression of ADAM8, 9, and 17 was significantly higher in grade 2 and 3 tumors and the expression of ADAM28 was highest in grade 2 tumors (data not shown).
With respect to tumor size, a significant increase was noted in MMP13 expression in locally invasive tumors with size over 4 cm (Fig. 4C) . No other significant differences about tumor size were found. Significant differences were also detected in the expression of degradome components in primary tumors of patients with lymph node metastases (Fig. 4D) . MMP9 showed significant decrease in expression in tumors with regional metastasis, whereas an increase in the expression of ADAM8 was noted in the same metastatic tumors (Fig. 4D) .
Discussion
The data presented in this study represent the first time that the expression of so many proteinases and their inhibitors has been studied as molecular markers in tumors of HNSCC patients. Utilization of a highly sensitive and specific quantitative technique (real-time PCR) to measure their expression in normal tissues from patients without carcinomas, peritumoral tissues adjacent to head and neck tumors, and two distinct tumor tissues (margin and nonnecrotic center tumor samples) of a fairly large patient cohort means that the role of these enzymes and their inhibitors in HNSCC can now be evaluated. The altered expression of proteinases and their inhibitors specifically in tumor cells were further investigated with cell lines derived from HNSCC tumors and with normal keratinocytes.
The patient cohort used in this study included 83 HNSCC patients of all ages, tumor stages, metastatic status, and primary tumor sites. Cell lines were established from 34 tumors of these patients. Together, the data presented correspond to a diverse and heterogeneous group of patients. However, to provide a descriptive degradome of HNSCC, the profiling data were presented in Fig. 1A and B and Table 3 as a whole with no selection of the patients from this group. It is recognized that this may dilute significant trends that could be attributed to individual patient and tumor characteristics. However, we have addressed this issue and some interesting differences between different clinicopathologic groups were apparent, as shown in Fig. 4 . However, it is likely that this patient cohort is still too small for many significant trends to be detected. In addition, the analyses of both normal tissue samples and tumor adjacent tissue samples also clearly show that the peritumoral adjacent tissue is strongly affected by the tumor and therefore cannot be considered as a normal tissue (Table 3 ; Fig. 1A and B) . We summarized below our key observations in relation to previous studies of particular proteinases and inhibitors in HNSCC.
MMPs and TIMPs. The descriptive degradome data of the MMPs for the most part confirm existing data on their expression in HNSCC. O-Charoenrat et al. (35) used semiquantitative RT-PCR analysis of tissue homogenates from 54 HNSCC patients to study many of the MMPs. In accordance with their data, we show that MMP1, 2, 3, 7, 9, 10, 11, 13, and TIMP1 were increased in tumor tissues compared with normal tissues (Table 3 ; Fig. 1 ). It was also possible to confirm some of these findings at the protein level (Fig. 2) . Furthermore, the analysis of HNSCC tumor cell lines showed clearly increased levels of MMP2, 7, 9, 10, 11, 13, 14, 16, 17, 23, 24 , and 25, indicating that these proteinases are produced by malignant cells of these tumors. These findings are in accordance with previous studies using immunohistochemistry and in situ hybridization, as well with recent studies with quantitative RT-PCR (28, 36) .
Interestingly, in divergence from the study of OCharoenrat et al. (35), we also show that the expression of MMP14 and TIMP2 was increased in tumor tissues compared with normal tissues in this study (Table 3 ; Fig. 1A and B) . Increased expression of MMP14 was also seen with SCC cell lines, indicating that this altered expression is indeed due to the malignant transformation of these cells (Fig. 3A) . Increased MMP14 in HNSCC tumors has been reported previously (37) . In addition, MMP14 is overexpressed by carcinoma-associated fibroblasts from HNSCC patients and MMP14 and MMP2 overexpression together has been shown to increase their invasion in vitro (38) . TIMP2 protein levels, while not previously reported to be increased in tumor tissues compared with normal tissues, correlate with lymph node metastasis and poor prognosis of early-stage oral HNSCC (39) , suggesting that TIMP2 also has a role in progression of HNSCC tumors. Cell-mediated activation of pro-MMP2 involves its binding to a complex formed by MMP14 and TIMP2. This anchorage of the pro-MMP2 molecule to the cell surface allows a second MMP14, which is not bound by TIMP2, to cleave and activate the pro-MMP2. Therefore, with high activation of MMP2 shown by the gelatin zymography (Fig. 2) , it is possible that the increased expression of both MMP14 and TIMP2 in these tumors could reflect their roles in the activation of MMP2, further enhancing the effect of upregulated MMP2 levels seen in both in vivo (Table 3 ; Fig. 1A and B) and in vitro (Fig. 3A) .
The remaining MMPs also showed significant increases in expression in the tumor tissues compared with adjacent peritumoral tissues. The only exception was MMP27 (Table 3) , which was the only MMP to significantly decrease in expression in tumor center and malignant cell lines, suggesting a potentially protective role of this proteinase in HNSCC progression. Certain differences were also detected in the expression of MMPs in locally invasive and metastatic primary tumors. Increased expression of MMP13 expression was noted in large locally invasive tumors (Fig. 4C) . In contrast, MMP9 expression was significantly decreased in tumors with lymph node metastasis (Fig. 4D) . TIMP4 was also the only TIMP significantly decreased in its expression in tumor tissues compared with adjacent tissue. Interestingly, these decreases in MMP27 and TIMP4 expression at the mRNA level have also been seen in other tumor types including prostate cancer (25) , glioma (40) , and breast cancers. 11 Although MMP27 cannot be detected by real-time PCR, TIMP4 is significantly decreased in expression in prostate cancers (25) . These findings suggest that both MMP27 and TIMP4, which have been little studied in the cancer field to date, are worthy of further functional investigation in relation to their roles in the pathophysiology of HNSCC. With further overlap in proteinase expressions between these three tumor types in those proteinases increased in HNSCC tumor tissues, this indicates that some proteinases and proteinase inhibitors might be particularly important in tumorigenesis of all types epithelial cancers.
ADAMs and ADAMTSs. Like the MMPs, the profiled ADAMs, which mediate growth factor shedding and regulate adhesion and motility, were significantly increased in their expression in the HNSCC tumor tissues compared with normal tissues (Table 2 ; Fig. 1A and B) . Previous studies have shown that several members of the ADAM family are upregulated in at least one cancer type (reviewed in ref. 13 ), but there are only a few studies about HNSCCs. There is some suggestion to their involvement in HNSCC as both ADAM10 (21) and ADAM12 (22) are overexpressed in oral HNSCCs. However, this is the first time that ADAM8, 9, 17, and 28 have been associated with HNSCC. Although detailed localization data are not yet available, the expression levels in the tumor-derived cell lines strongly suggest that at least ADAM17 and 28 are expressed by the malignant cells in tumors (Fig. 3A) . These results were also confirmed at the protein level ADAM8, 9, and 28 in SCC cell lines (Fig. 3B) . In addition, increased expression of ADAM8 was noted in the metastatic tumors (Fig. 4D ). Together these data strongly suggest that certain ADAMs, most convincingly ADAM8, ADAM17, and ADAM28, have an important role in HNSCC pathogenesis. Detection of the 42-kDa band in the ADAM28 Western blot also showed that AD-AM28 is proteolytically activated in a subset of HNSCC cell lines (Fig. 3B) . ADAM28 has shown to be overexpressed in breast carcinoma cells and to increase their proliferation (41) . Accordingly, our data suggest that ADAM28 could also function in tumorigenesis of HNSCCs.
Studies about ADAMTSs in human cancers have revealed different and often contradictory roles of certain ADAMTSs between different types of cancer (42) . In particular, ADAMTS1 and 8 are antiangiogenic and thus potentially antagonistic to tumor growth (43) . However, ADAMTS1 has been shown to both promote or inhibit breast tumor growth and metastasis in vivo, depending on whether it is present as a full-length or cleaved molecule (44) . Despite this, there is growing recognition that several ADAMTS family members are tumor suppressors (9) . This is the case for ADAMTS15 whose elevated expression correlates with favorable outcome in patients with breast cancer (45) and which acts as a functional tumor suppressor in colorectal cancer (46) . Recently, of great relevance, ADAMTS9 is deleted or silenced by methylation in esophageal SCC (47) . We found only one previous study that has profiled ADAMTSs in the context of HNSCC (48) .
The results of their study showed that the mRNA levels of ADAMTS1, 4, 5, 8, 9 , and 15 were all reduced in HNSCC primary tumors compared with paired noncancerous tissues in a cohort of 20 patients. Interestingly, these authors found all but ADAMTS4 increased in metastatic tissue compared with primary tumor tissue. The results of our study agree with these findings when comparing tumor center and peritumoral adjacent tissue, with the exception of ADAMTS8 (Table 3 ; Fig. 1A and B) . However, when comparing tumor center samples to normal tissue samples, ADAMTS1, 5, 8, and 15 were increased in expression, whereas ADAMTS9 was the only analyzed ADAMTS, the expression of which did not significantly differ between the center tumor tissues and normal tissues (Table 3 ; Fig. 1A and B) . Tumor cell lines established from HNSCCs showed clearly decreased expression of ADAMTS5 and 9, and strongly increased expression of ADAMTS1, 8, and 15 compared with normal keratinocytes (Fig. 3A) . These results show that there is major dysregulation of multiple members of the ADAMTS family, i.e., ADAMTS1, 8, and 15 in HNSCCs, suggesting a role for these proteinases in HNSCC progression.
In conclusion, the current study provides the most comprehensive analysis to date of the expression of metalloproteinases and their inhibitors in HNSCC. In addition to endorsing roles for several previously studied MMPs and TIMPs, these data highlight several additional novel metalloproteinase genes showing altered expression in tumor tissues and cell lines, including ADAM8, ADAM17, ADAM28, ADAMTS1, ADAMTS8, ADAMTS9, and ADAMTS15. Based on emerging knowledge from other tumor types, further studies into the clinical significance of these novel HNSCC-associated proteinases are likely to prove fruitful.
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